Beta-Amyloid Binding Peptides for Alzheimer's Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease are ineffective in preventing or curing the condition, with existing drugs providing only temporary benefits and significant side effects, and there is a need for alternative approaches that can address β-amyloid accumulation and toxicity.
Innovation Solution
Development of proteins and peptides, such as PK-4 and its derivatives, which bind β-amyloids and inhibit protein kinase C, offering potential therapeutic options for treating and preventing Alzheimer's by modulating β-amyloid aggregation, generation, and toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acetylcholine esterase inhibitors are used to treat Alzheimer's disease, then cognition is temporarily improved, but severe side effects occur and the disease progression is not stopped
Solution Approach 1:
The patent uses beta-amyloid binding proteins as intermediary molecules that sequester circulating beta-amyloid peptides, preventing them from crossing the blood-brain barrier and causing neurotoxicity. This mediator approach addresses the root cause (beta-amyloid accumulation) rather than just managing symptoms, thereby improving reliability of treatment while avoiding the severe side effects associated with cholinesterase inhibitors
Solution Approach 2:
The invention extracts and removes the harmful beta-amyloid peptides from circulation through high-affinity binding proteins. By taking out the toxic agent (beta-amyloid) from the system before it can cause damage in the brain, the treatment achieves reliable cognitive benefits without the side effects that result from allowing beta-amyloid accumulation
2Reliability
If beta-amyloid accumulation is allowed to proceed, then disease pathology develops, but current treatments cannot prevent or cure the condition
Solution Approach 1:
The patent employs preliminary action by administering beta-amyloid binding proteins that proactively sequester circulating beta-amyloid peptides before they can accumulate in the brain and initiate pathological cascades. This preventive approach addresses beta-amyloid accumulation at its source in circulation, providing long-term disease prevention rather than temporary symptom management
Solution Approach 2:
The beta-amyloid binding proteins serve as intermediary agents that continuously bind and neutralize beta-amyloid in circulation. This intermediary mechanism provides sustained protection against beta-amyloid toxicity, extending the duration of therapeutic effect and enabling long-term disease modification
3Reliability
If beta-amyloid is sequestered and clearance is promoted, then Aβ burden is reduced, but effective drugs or treatments are currently unavailable
Solution Approach 1:
The patent utilizes the body's own clearance mechanisms enhanced by beta-amyloid binding proteins. The binding proteins facilitate spontaneous clearance of beta-amyloid through existing physiological pathways (renal filtration, reticuloendothelial system) without requiring complex external intervention systems, thereby achieving reliable beta-amyford clearance while simplifying manufacturing and drug delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides demonstrate high affinity binding to β-amyloids, inhibit their aggregation, and reduce neurotoxicity, showing promise in reducing β-amyloid burden and improving cognitive function, with potential for long-term therapeutic benefits without severe side effects.
Implementation Method 1
A first aspect of the invention provides for an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, and SEQ ID NO. 5... which bind (β-amyloids
Implementation Method 2
The protein PK-4 and its peptide derivatives are found to have this property [protein kinase C inhibiting properties]
Data Source
AI summary
A protein kinase C inhibitor that binds β-amyloid and its peptide derivatives with the same function are disclosed. These may be useful in the treatment of Alzheimer's disease, for example as pseudo vaccines comprising antibodies, or as part of fusion proteins which are able to pass through cell membranes or through the blood-brain barrier. Methods of using the PKC inhibitor and its peptide derivatives for treating Alzheimer's disease are also disclosed.